Provided by Integrity Continuing Education, Inc.
This activity is supported by independent educational grants from Jazz Pharmaceuticals, Inc.
Treatment of excessive daytime sleepiness (EDS) in obstructive sleep apnea (OSA)
OSA is a highly prevalent disorder that is growing in incidence in tandem with an obesity epidemic believed to be at the etiologic core of this chronic respiratory disorder. EDS is the most common (but not universal) symptom of OSA — it is also the most overlooked and neglected. While many healthcare providers (HCPs) are appropriately managing breathing obstruction with continuous positive airway pressure (CPAP), EDS often remains under-identified and unassessed, therefore chronically unaddressed.
Perhaps the assumption is that CPAP will resolve this bothersome issue or that EDS, in and of itself, is not significant enough to treat. Research reveals that both suppositions are incorrect. Studies have revealed that even regular, consistent use of CPAP does not diminish persistent sleepiness in up to half of OSA patients. Other research has revealed that disturbed sleep plays a strong role in the etiology of obesity and cardiovascular disease risk, both of which are common in patients with OSA. EDS also reduces quality of life (QOL) and ability to function well in daily life, while simultaneously increasing the risk for motor vehicle or workplace accidents. Outcomes for patients with OSA and EDS could be improved if physicians and other clinicians learned to acknowledge, ask about, and manage EDS in their OSA patients who continue to struggle with sleepiness despite adherence to CPAP.
Kori Ascher, DO
Pulmonary, Critical Care, and Sleep Medicine
University of Miami
Seema Khosla, MD, FCCP, FAASM
North Dakota Center for Sleep
Fargo, North Dakota
This educational activity has been designed to meet the needs of sleep specialists, including neurologists, psychiatrists, and pulmonologists; primary care providers; nurse practitioners; physician assistants; and other healthcare professionals (HCPs) involved in the care of patients with residual EDS in patients with obstructive sleep apnea (OSA).
Upon completion of this educational activity, participants should be able to:
There are no fees for participating and receiving CME credit for this activity. During the period of December 9, 2021 through December 9, 2022 participants must:
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.
Physician Continuing Education
Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Integrity Continuing Education, Inc. designates this other activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or firstname.lastname@example.org.
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
Kori Ascher, DO has no real or apparent conflicts of interest to disclose.
Seema Khosla, MD, FCCP, FAASM
Stocks (no consulting): Inspire Pharmaceutical, Inc.
Hosting a discussion session (no recording): Jazz Pharmaceuticals, Inc
The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer below 8 is not recommended.
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.